<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602952</url>
  </required_header>
  <id_info>
    <org_study_id>IY5511A1201</org_study_id>
    <nct_id>NCT01602952</nct_id>
  </id_info>
  <brief_title>Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI</brief_title>
  <official_title>A Phase I/II Multicenter Study of IY5511HCl in Philadelphia Chromosome Positive Chronic Myeloid Leukemia Patients Without Optimal Response or Tolerance to Bcr-Abl Tyrosine Kinase Inhibitors (Imatinib and/ or Dasatinib, Nilotinib)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Il-Yang Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Il-Yang Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I/II multicenter study of IY5511HCl in Philadelphia chromosome positive chronic&#xD;
      myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase&#xD;
      inhibitors (Imatinib and/ or Dasatinib, Nilotinib) In this study, The efficacy and safety of&#xD;
      CML patients who are resistant or intolerable to imatinib in the Chronic and Accelerated&#xD;
      phases.&#xD;
&#xD;
      Phase 1&#xD;
&#xD;
      1. To investigate the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicity (DLT) of&#xD;
      oral Radotinib HCl bid (twice daily) in the Philadelphia chromosome-positive CML subjects who&#xD;
      are resistant, suboptimal responsive, or intolerant to imatinib OR resistant or intolerant to&#xD;
      at least one second-generation targeted anticancer agent while being resistant, suboptimal&#xD;
      responsive, or intolerant to imatinib simultaneously.&#xD;
&#xD;
      Phase 2&#xD;
&#xD;
        1. To investigate safety of oral Radotinib HCl in CML patients who are resistant or&#xD;
           intolerable to imatinib in the chronic and accelerated phases.&#xD;
&#xD;
        2. To evaluate hematologic and cytogenetic efficacy of oral Radotinib HCl in CML patients&#xD;
           who are resistant or intolerable to imatinib in the chronic and accelerated phases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, open-label, Phase 1/2 clinical trial of Radotinib HCl, a&#xD;
      targeted anticancer agent that inhibits the Bcr-Abl oncoprotein. It is aimed at determining&#xD;
      the optimal therapeutic dose and confirming safety and efficacy of Radotinib HCl. Phase 1&#xD;
      study began at St. Mary's hospital in Korea and Phase 2 study is ongoing at 9 Korean sites&#xD;
      and about 7 sites in China, India and Thailand will take part in Phase 2. After determination&#xD;
      of a safe and proper therapeutic dose in Phase 1, Phase 2 began continuously to evaluate&#xD;
      efficacy in chronic and accelerated phases. Before the start of the Phase 2 trial, interim or&#xD;
      final reports for the Phase 1 trial were reviewed by the Korean Food and Drug Administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 13, 2018</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the Maximum Tolerated Dose(Phase 1)</measure>
    <time_frame>12 month</time_frame>
    <description>Radotinib will be given orally twice daily. Dose will be increased until it reaches MTD or the blood concentration of Radotinib stops rising</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Complete hematologic response(CHR)(Phase 2)</measure>
    <time_frame>12 months</time_frame>
    <description>Main parameters for response assessment in the chronic and accelerated phases include Major Hematologic Responses (MR; No Evidence of Leukemia or NEL + Complete Hematologic Response or CHR) lasting for 4 weeks and at least one major cytogenetic response (MCyR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the Dose Limiting Toxicity(Phase 1)</measure>
    <time_frame>12 months</time_frame>
    <description>The initial cohort will include 3 subjects who will receive 100mg Radotinib daily. If DLT is observed in one of the 3 subjects, the same dose will be given to 3 more subjects to evaluate safety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete Cytogenetic Response(CCyR)(Phase 2)</measure>
    <time_frame>12 months</time_frame>
    <description>Cytogenetic response rate will be calculated as the percentage of Ph+ bone marrow metaphases as follows at least 20 bone marrow metaphases should be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events(Phase 1&amp; Phase 2)</measure>
    <time_frame>12 months</time_frame>
    <description>All adverse events recorded during the study will be itemized and summarized. Severity, relation to the study medication, and seriousness will be summarized for each adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival or PFS</measure>
    <time_frame>12 months</time_frame>
    <description>It is defined as the duration from the first day of administration to the earliest day of disease progression or death for certain causes. In subjects who have shown response, disease progression is defined as loss of MCyR.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Leukemia</condition>
  <condition>Leukemia, Myeloid</condition>
  <condition>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</condition>
  <condition>Philadelphia Chromosome</condition>
  <condition>Hematologic Diseases</condition>
  <arm_group>
    <arm_group_label>Radotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 : 200mg/kg or 1200mg/m^2&#xD;
Phase 2 : 400mg Bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radotinib</intervention_name>
    <description>50mg, 100mg or 200mg Capsule BID</description>
    <arm_group_label>Radotinib</arm_group_label>
    <other_name>IY5511HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Phase I&#xD;
&#xD;
          1. Age ≥ 18 years old&#xD;
&#xD;
          2. Ph+ CML patients who are resistant at chronic, accelerate, and acute phase, or&#xD;
             suboptimal responsive, or intolerant to imatinib or resistant or intolerant to at&#xD;
             least one second-generation targeted anticancer agent while being resistant,&#xD;
             suboptimal responsive, or intolerant to imatinib simultaneously.&#xD;
&#xD;
          3. WHO Performance status of ≤2&#xD;
&#xD;
          4. Patients must have the following laboratory values With normal liver and renal&#xD;
             function&#xD;
&#xD;
          5. Patients who have received interferon, other anti cancer drug or radiotherapy &gt; 1 week&#xD;
             prior to starting study drug.&#xD;
&#xD;
        Phase II&#xD;
&#xD;
          1. Age ≥ 18 years old&#xD;
&#xD;
          2. Ph+ CML patients in chronic or accelerated phase who are resistant or intolerant to&#xD;
             Imatinib mesylate&#xD;
&#xD;
          3. WHO Performance status of ≤2&#xD;
&#xD;
          4. Patients must have the following laboratory values With normal liver and renal&#xD;
             function&#xD;
&#xD;
          5. Patients who have received interferon, other anti cancer drug or radiotherapy &gt; 1 week&#xD;
             prior to starting study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Phase I&#xD;
&#xD;
          1. CNS infiltration&#xD;
&#xD;
          2. Impaired cardiac function, including any one of the followings.&#xD;
&#xD;
               -  LVEF &lt;45% as determined by MUGA scan or echocardiogram&#xD;
&#xD;
               -  Clinically significant resting bradycardia&#xD;
&#xD;
          3. Severe GI disease that may cause drug absorption problem of study drug&#xD;
&#xD;
          4. Use of therapeutic Warfarin&#xD;
&#xD;
          5. Acute or chronic liver or renal disease&#xD;
&#xD;
          6. Other concurrent severe and/or uncontrolled medical conditions&#xD;
&#xD;
          7. Treatment with any hematopoietic colony-stimulating growth factors ≤1 week prior to&#xD;
             starting study drug.&#xD;
&#xD;
          8. Patients who are currently receiving treatment with medications have the potential to&#xD;
             prolong the QT interval&#xD;
&#xD;
          9. Patients who have received Imatinib, interferon, other anti cancer drug or&#xD;
             chemotherapy ≤ 1 week&#xD;
&#xD;
         10. Patients who have received Nilotinib and Dasatinib ≤4 weeks prior to starting study&#xD;
             drug.&#xD;
&#xD;
         11. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or&#xD;
             who have not recovered from side effects of such therapy&#xD;
&#xD;
         12. Patients who are pregnant or breast-feeding or adults of reproductive potential not&#xD;
             employing an effective method of birth control.&#xD;
&#xD;
         13. Patients not to agree using birth control during the study and for up 3 months&#xD;
             following study completion.&#xD;
&#xD;
        15. HIV infection&#xD;
&#xD;
        Phase II&#xD;
&#xD;
          1. Blast phase CML&#xD;
&#xD;
          2. CNS infiltration&#xD;
&#xD;
          3. Impaired cardiac function, including any one of the following&#xD;
&#xD;
               -  LVEF&lt; 45% as determined by MUGA scan or echocardiogram&#xD;
&#xD;
               -  Use of Cardiac pacemaker&#xD;
&#xD;
               -  ST depression &gt; 1mm in 2 or more leads and/or T wave inversions in 2 or more&#xD;
                  contiguous leads&#xD;
&#xD;
               -  Congenital long QT syndrome&#xD;
&#xD;
               -  History of, or presence of significant ventricular or atrial tachyarrhythmias&#xD;
&#xD;
               -  Clinically significant resting bradycardia&#xD;
&#xD;
               -  QTcF&gt; 480 msec on screening ECG&#xD;
&#xD;
               -  Right bundle branch block + left anterior hemiblock, Bifascicular block&#xD;
&#xD;
               -  Angina pectoris&#xD;
&#xD;
          4. Severe GI disease that may cause drug absorption problem of study&#xD;
&#xD;
          5. Use of therapeutic Warfarin&#xD;
&#xD;
          6. Acute or chronic liver or renal disease&#xD;
&#xD;
          7. Other concurrent severe and/or uncontrolled medical conditions&#xD;
&#xD;
          8. Treatment with any hematopoietic colony-stimulating growth factors ≤1 week prior to&#xD;
             starting study drug.&#xD;
&#xD;
          9. Patients who are currently receiving treatment with medications have the potential to&#xD;
             prolong the QT interval&#xD;
&#xD;
         10. Patients who have received Imatinib, interferon, other anti cancer drug or&#xD;
             chemotherapy ≤ 1 week&#xD;
&#xD;
         11. Patients who have received wide field radiotherapy ≤4 weeks prior to starting study&#xD;
             drug.&#xD;
&#xD;
         12. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or&#xD;
             who have not recovered from side effects of such therapy&#xD;
&#xD;
         13. Patients who are pregnant or breast-feeding or adults of reproductive potential not&#xD;
             employing an effective method of birth control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>IL-yang Pharm</last_name>
    <role>Study Director</role>
    <affiliation>IL-YANG Pharmaceutical.Co.,Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>741-234</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Mumbai</city>
        <state>Mazagaon</state>
        <zip>512-364</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Daegu</city>
        <state>Buk-gu</state>
        <zip>511-230</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Jeonju</city>
        <state>Deokjin-gu</state>
        <zip>212-789</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Ulsan</city>
        <state>Dong-gu</state>
        <zip>411-978</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Anyang-si</city>
        <state>Dongan-gu</state>
        <zip>751-231</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Hwasun</city>
        <state>Hwasun-eup</state>
        <zip>322-511</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Seoul</city>
        <state>Jongro-ku</state>
        <zip>231-855</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Busan</city>
        <state>Seo-gu</state>
        <zip>400-321</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Suwon</city>
        <state>Yeongtong-gu</state>
        <zip>781-512</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Bangkok</city>
        <state>Phyathai</state>
        <zip>215-714</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 20, 2012</study_first_submitted>
  <study_first_submitted_qc>May 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2012</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radotinib</keyword>
  <keyword>CML-CP, AP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

